Home / Current Affairs / Gilead expands hepatitis-C licensing pacts

Gilead expands hepatitis-C licensing pacts

US-based drug firm Gilead Sciences has expanded its hepatitis-C generic licensing agreements with India-based firms to include investigational pan-genotypic medicine GS-5816 as part of a single tablet regimen that combines it and sofosbuvir.

The investigational NS5A inhibitor GS-5816 is being evaluated in Phase-III clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis-C, Gilead Sciences Inc said in a statement on Monday.

“The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries…,” it added.

These countries together account for 54 per cent of the total worldwide population of individuals infected with the hepatitis-C virus, it added.

Commenting on the development, Gilead Sciences Corporate and Medical Affairs Executive Vice-President Gregg H Alton said: “Today’s announcement marks an important milestone in Gilead’s effort to make effective hepatitis C treatment accessible to as many patients, in as many places, as quickly as possible.”


Check Also

Pakistan players target first World Cup win against India

If you talk to any Pakistani player ahead of Sunday’s clash against ...

Sunanda case: Tharoor quizzed once again

Congress MP Shashi Tharoor was today questioned by the Special Investigation Team ...